样式: 排序: IF: - GO 导出 标记为已读
-
Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11 Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-22 Juehua Gao, Lucas Santana-Santos, Lucy Fu, Emily Alvey, Qing Chen, Kristy Wolniak, Zongjun Xia, Barina Aqil, Amir Behdad, Peng Ji, Madina Sukhanova, Yasmin Abaza, Jessica K. Altman, Yi-Hua Chen, Xinyan Lu
This study assesses the clinical significance of additional cytogenetic abnormalities (ACAs) and/or the deletion of 3′CBFB (3′CBFBdel) resulting in unbalanced CBFB::MYH11 fusion in acute myeloid leukemia (AML) with inv (16)/t(16;16)/CBFB::MYH11.
-
Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-21 Danai Dima, Razan Mansour, James A. Davis, Megan Minchak, Utkarsh Goel, Rawan Atallah, Emerson Logan, Carine Tabak, Aliya Rashid, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi
We conducted a multicenter retrospective study to analyze the safety and efficacy of DPd versus DKd in daratumumab naïve RRMM patients treated in real-world practice.
-
The EASEMENT study: A multicentre, observational, cross‐sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable‐containing or fully oral therapies Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-23 Robert Ayto, Ombretta Annibali, Patricia Biedermann, Montserrat Roset, Emilio Sánchez, Rami Kotb
ObjectiveAs multiple myeloma (MM) therapies advance, understanding patients', caregivers', and physicians' perspectives on, and satisfaction with, available treatment options and their impact on quality of life (QoL), is important.MethodsEASEMENT is a real‐world, observational, cross‐sectional study conducted in 19 sites within the UK, Canada, and Italy using retrospective chart reviews and surveys
-
Value of hemophagocytosis in the diagnosis of hemophagocytic lymphohistiocytosis in critically ill patients Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-18 Peter Nyvlt, Friederike S. Schuster, Jana Ihlow, Patrick Heeren, Claudia Spies, Josephine Hiesgen, Thomas Schenk, Ann-Christin von Brünneck, Jörg Westermann, Frank M. Brunkhorst, Paul La Rosée, Gritta Janka, Cornelia Lachmann, Gunnar Lachmann
Ferritin is an established biomarker in the diagnosis of secondary hemophagocytic lymphohistiocytosis (HLH), which is diagnosed by the HLH-2004 criteria. Among these criteria, detection of hemophagocytosis through invasive procedures may delay early life saving treatment. Our aim was to investigate the value of hemophagocytosis in diagnosing HLH in critically ill patients.
-
Recombinant factor IX Fc for the treatment of hemophilia B Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-19 Rolf Ljung, Davide Matino, Amy D. Shapiro
Current hemophilia B treatment guidelines recommend routine prophylaxis with factor IX (FIX) replacement products, tailored to maintain plasma activity at levels that will prevent bleeds. However, plasma FIX activity may not be the primary determinant or best indicator of hemostatic efficacy due to its extravascular distribution. FIX replacement therapy has evolved to include extended half‐life (EHL)
-
Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-19 Jan‐Michel Heger, Yannick d'Hargues, Fanni Kleinert, Julia Mattlener, Jonathan Weiss, Fabian Franzen, Christian Becker, Kerstin Becker, Philipp Gödel, Marcel Schmiel, Jörn Meinel, Ruth Flümann, Florian Simon, H. Christian Reinhardt, Peter Borchmann, Sven Borchmann, Hyatt Balke‐Want, Gero Knittel, Bastian von Tresckow
Although several promising approaches for the treatment of relapsed/refractory diffuse large B‐cell lymphoma (rrDLBCL) have been approved recently, it remains unclear which patients will ultimately achieve long‐term responses. Circulating tumor (ct)DNA sequencing has emerged as a valuable tool to assess minimal residual disease (MRD). Correlations between MRD and outcomes have been shown in previously
-
Featured Cover Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-15 Wolfgang Miesbach, Annette von Drygalski, Clive Smith, Krupa Sivamurthy, Karen Pinachyan, Debbie Bensen-Kennedy, Douglass Drelich, Roshni Kulkarni
-
Development and initial validation of the AL-PROfile patient-reported outcome measure in light chain (AL) amyloidosis Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-13 Anita D'Souza, Aniko Szabo, Idayat Akinola, Muriel Finkel, Kathryn E. Flynn
To evaluate the psychometric properties of the AL-PROfile, a patient-reported outcome measure combining the Patient-Reported Outcomes Measurement Information System (PROMIS)-29, two items from PROMIS Cognitive Function, and select Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) items.
-
Pancreas-related persisting sequelae in ALL survivors with a history of asparaginase-associated pancreatitis: A part of the ALL-STAR study Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-13 Mette Tiedemann Skipper, Niels Birkebæk, Rikke Beck Jensen, Cecilie Utke Rank, Ruta Tuckuviene, Peder Skov Wehner, Trine-Lise Lambine, Arne Hørlyck, Kjeld Schmiegelow, Thomas Leth Frandsen, Liv Andrés-Jensen, Birgitte Klug Albertsen
Asparaginase-associated pancreatitis (AAP) occurs in up to 18% of patients treated for acute lymphoblastic leukemia (ALL); however, long-term sequelae are largely unexplored. We aimed to explore pancreatic sequelae among ALL survivors with and without AAP.
-
Systematic review of hematopoietic stem cell gene therapy approach in thalassemia: Comparative analysis in animal models Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-11 Indira Laksmi Maharani, Muhammad Hafizh Zauhari, Rakean Ahmad Kiansantang, Razzan Satria Wibowo, Rizqi Najla Humaira, Adisti Dwijayanti, Imelda Rosalyn Sianipar
Hematopoietic stem cell (HSC) gene therapy has shown potential as a therapeutic approach for thalassemia in recent years. However, a comparison of the varying gene therapy methods of HSC gene therapy in thalassemia has never been reviewed. This study aims to evaluate the utilization of HSC gene therapy approaches in animal models of thalassemia. A systematic review was conducted in five databases:
-
Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-11 Anke Gerhardt, Steffen Dörfel, Holger Schulz, Rudolf Schlag, Lukas Vornholz, Sonja Nejad-Asgari, Manfred Welslau
To assess treatment adherence, effectiveness and safety outcomes of patients with chronic lymphocytic leukaemia (CLL) receiving ibrutinib in a real-world setting.
-
Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-11 Yue Sun, Gelan Zhu, Hua Zhong
Acute myeloid leukemia (AML) is distinguished by clonal growth of myeloid precursor cells, which impairs normal hematopoiesis. Minimal residual disease (MRD) refers to the residual leukemia cells that persist after chemotherapy. Patients who test positive for MRD have a higher likelihood of experiencing a recurrence, regardless of the specific chemotherapy approach used. Multi-parameter flow cytometry
-
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-09 Alessandro Laganà, Mauro Passucci, Sara Pepe, Emilia Scalzulli, Ida Carmosino, Alessandro Costa, Maria Laura Bisegna, Claudia Ielo, Maurizio Martelli, Massimo Breccia
Myelofibrosis (MF) is a clonal Philadelphia chromosome negative myeloproliferative neoplasm (Ph-MPN). MF is featured by an inflammatory condition that can also drive the progression of disease. Ruxolitinib (ruxo) is the-first-in-class Jak1/2 inhibitor approved for treatment of MF, proved to reduce spleen volume and decrease symptom burden. In various malignancies neutrophil-to-lymphocyte ratio (NLR)
-
An artificial intelligence-driven predictive model for pediatric allogeneic hematopoietic stem cell transplantation using clinical variables Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-09 Carlos Echecopar, Inés Abad, Víctor Galán-Gómez, Yasmina Mozo del Castillo, Luisa Sisinni, David Bueno, Beatriz Ruz, Antonio Pérez-Martínez
Hematopoietic stem cell transplantation (HSCT) is a procedure with high morbidity and mortality. Identifying patients for maximum benefit and risk assessment is crucial in the decision-making process. This has led to the development of predictive risk models for HSCT in adults, which have limitations when applied to pediatric population. Our goal was to develop an automatic learning algorithm to predict
-
Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-05 Nadine Kutsch, Philipp Gödel, Conrad-Amadeus Voltin, Michael Hallek, Christof Scheid, Peter Borchmann, Udo Holtick
Patients with Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL-RT) face a dismal prognosis. A 51-year-old female patient diagnosed with CLL with deletion (17p) in 2009. CLL treatment included chemoimmunotherapy and targeted substances. DLBCL-RT was diagnosed in November 2016. After receiving an allogeneic hematopoietic stem cell transplantation
-
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-04 Sibylle C. Mellinghoff, Sandra Robrecht, Rosanne Sprute, Leonie Mayer, Leonie M. Weskamm, Christine Dahlke, Henning Gruell, Finn Teipel, Hans A. Schlößer, Klara Siepmann, Martin Thelen, Anna-Maria Fink, Kirsten Fischer, Florian Klein, Marylyn M. Addo, Androniki Kolovou, Oliver A. Cornely, Barbara Eichhorst, Michael Hallek, Petra Langerbeins
Preventing severe COVID-19 remains a priority globally, particularly in the immunocompromised population. As shown in healthy individuals, immunity against SARS-CoV-2 can be yielded by previous infection, vaccination, or both (hybrid immunity). The objective of this observation study was to investigate hybrid immunity in patients with chronic lymphocytic leukemia (CLL).
-
Disseminated intravascular coagulation score evolution in 48 h predicts early death in acute promyelocytic leukemia patients Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-02 Joana Brioso Infante, Graça Vasconcelos Esteves, João Raposo, João Forjaz de Lacerda
Early death (ED) is the unsolved issue of acute promyelocytic leukemia (APL). The disseminated intravascular coagulation (DIC) score has been proposed as a marker of bleeding and death in APL; whether its temporal evolution predicts outcomes in APL is unknown. We evaluated whether an increasing score 48 h after diagnosis associates with ED.
-
Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-31 Martin H. J. Wiesen, Jannik Stemler, Cornelia Fietz, Carolin Joisten, Oliver A. Cornely, Nick Verougstraete, Thomas Streichert, Carsten Müller
Midostaurin is an oral multitargeted tyrosine kinase inhibitor for the treatment of acute myeloid leukemia (AML). Therapeutic drug monitoring of midostaurin may support its safe use when suspecting toxicity or combined with strong CYP3A4 inhibitors.
-
Late transplant-associated thrombotic microangiopathy verified in bone marrow biopsy specimens is associated with chronic GVHD and viral infections Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-20 Wolfgang Hill, Karl Sotlar, Anke Hautmann, Hans-Jochem Kolb, Johanna Ullmann, Andreas Hausmann, Michael Schmidt, Johanna Tischer, Thu-Trang Pham, Andreas Rank, Manuela A. Hoechstetter
To describe late transplant-associated thrombotic microangiopathy (TA-TMA) as chronic endothelial complication in bone marrow (BM) after allogeneic hematopoietic stem cell transplantation (HSCT).
-
JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-16 Christina Schjellerup Eickhardt-Dalbøge, Henrik V. Nielsen, Kurt Fuursted, Christen Rune Stensvold, Lee O' Brien Andersen, Berit Lilje, Morten Kranker Larsen, Lasse Kjær, Sarah Friis Christensen, Trine Alma Knudsen, Vibe Skov, Anders Lindholm Sørensen, Christina Ellervik, Lars Rønn Olsen, Jens Jørgen Elmer Christensen, Xiaohui Chen Nielsen, Hans Carl Hasselbalch, Anna Cäcilia Ingham
Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis.
-
Pattern of use and clinical outcomes with rIX-FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real-world study Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-15 Paola Giordano, Berardino Pollio, Gianluca Sottilotta, Chiara Biasoli, Filomena Daniele, Raimondo De Cristofaro, Flora Peyvandi, Maria Rosaria Villa, Giancarlo Castaman
To evaluate pattern of use and clinical outcomes in pediatric/adolescent patients enrolled in the IDEAL study.
-
Comparison of telomere length in patients with bone marrow failure syndromes and healthy controls Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-12 Aruna Barade, Kavitha M. Lakshmi, Anu Korula, Fouzia N. Abubacker, Uday P. Kulkarni, Aby Abraham, Vikram Mathews, Biju George, Eunice S. Edison
During normal aging, telomeric DNA is gradually lost in dividing somatic cells, and critically short telomeres lead to replicative senescence, apoptosis, or chromosomal instability. We studied telomere length in bone marrow failure syndromes (BMFS) compared to normal healthy population.
-
Soluble mannose receptor: A potential biomarker in Gaucher disease Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-10 Brendan Beaton, Derralynn A. Hughes
Soluble mannose receptor (sMR) relates to mannose receptor expression on macrophages, and is elevated in inflammatory disorders. Gaucher disease (GD) has altered macrophage function and utilises mannose receptors for enzyme replacement therapy (ERT) endocytosis. sMR has not previously been studied in GD.
-
A post hoc analysis of PROTECT VIII kids assessing long-term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-09 Sanjay Ahuja, Tina Biss, Monika Maas Enriquez, Maria Elisa Mancuso, MacGregor Steele, Gili Kenet
The safety and efficacy of the extended half-life factor VIII (FVIII) product damoctocog alfa pegol (BAY 94-9027, Jivi®) has been demonstrated in the PROTECT VIII Kids study (NCT01775618), where male previously-treated patients (PTPs) aged <12 years old with severe haemophilia A and ≥ 50 exposure days (EDs) were treated prophylactically. The PROTECT VIII Kids extension study assessed the long-term
-
Transcriptome analysis of primary adult B-cell lineage acute lymphoblastic leukemia identifies pathogenic variants and gene fusions, and predicts subtypes for in depth molecular diagnosis Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-08 Mirjam Podgorica, Elsa Drivet, Jonas Krag Viken, Alyssa Richman, Johanne Vestbøstad, Peter Szodoray, Ann Kristin Kvam, Hilde Skuterud Wik, Geir E. Tjønnfjord, Ludvig A. Munthe, Seth Frietze, Hilde Schjerven
B-cell acute lymphoblastic leukemia (B-ALL) is classified into subgroups based on known driver oncogenes and molecular lesions, including translocations and recurrent mutations. However, the current diagnostic tests do not identify subtypes or oncogenic lesions for all B-ALL samples, creating a heterogeneous B-ALL group of unknown subtypes.
-
Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-10 Jonas Kassow Gronlund, Christopher Veigaard, Caroline Juhl-Christensen, Anne-Sofie Skou, Dorte Melsvik, Hans Beier Ommen
Follow-up after allogeneic transplantation in acute myeloid leukaemia (AML) is guided by measurable residual disease (MRD) testing. Quantitative polymerase chain reaction (qPCR) is the preferred MRD platform but unfortunately, 40%–60% of AML patients have no high-quality qPCR target. This study aimed to improve MRD testing by utilising droplet digital PCR (ddPCR). ddPCR offers patient-specific monitoring
-
Trends in underlying causes of death in allogeneic hematopoietic cell transplant recipients over the last decade Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-06 Andreas Søborg, Joanne Reekie, Henrik Sengeløv, Caspar Da Cunha-Bang, Thomas Kromann Lund, Christina Ekenberg, Isabelle Paula Lodding, Kasper Sommerlund Moestrup, Louise Lundgren, Jens D. Lundgren, Neval Ete Wareham
Improved survival after hematopoietic cell transplantation (HCT) and an increasingly comorbid transplant population may give rise to new trends in the causes of death.
-
Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-03 Nobuhiko Yamauchi, Dai Maruyama
Chimeric antigen receptor (CAR) T-cell therapy has become a commercially available treatment option for relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) with two or more lines of prior therapies, and recently for high-risk r/r DLBCL with one prior line of therapy. The successful development of CAR T-cell therapy for multiple relapsed DLBCL has led to a boom in subsequent trials that
-
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-06 Eugenio Galli, Elisabetta Metafuni, Carlo Gandi, Maria Assunta Limongiello, Sabrina Giammarco, Andrea Mattozzi, Rosaria Santangelo, Andrea Bacigalupo, Federica Sorà, Patrizia Chiusolo, Simona Sica
Hemorrhagic cystitis (HC) is a highly impacting complication in allogeneic hematopoietic stem cell transplantation (HSCT), occurring in 12%–37% of patients. The impact of transplant- and patient-specific variables has been described, with a possible role for JCV and BKV, which may be cooperating with cytomegalovirus (CMV). Here, we analyze 134 letermovir-exposed, CMV-free patients, treated with the
-
Feasibility, accuracy, and usability analysis of MapAML, a first-in-class app for integrated diagnosis in acute myeloid leukemia Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-03 Thaís B. Moyen, Victoria Tomaz, Paulo V. Campregher
Performing a comprehensive diagnosis of acute myeloid leukemia (AML) is complex and involves the integration of clinical information, bone marrow morphology, immunophenotyping, cytogenetic, and molecular analysis, which can be challenging to the general hematologist. The aim of this study was to evaluate the usability and accuracy of MapAML, a smartphone app for integrated diagnosis in AML, created
-
Effects of tertiary palliative care on the pattern of end-of-life care in patients with hematologic malignancies in Korea Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-28 Dong Hyun Kim, Jeonghwan Youk, Ja Min Byun, Youngil Koh, Junshik Hong, Tae Min Kim, Inho Kim, Sung-Soo Yoon, Shin Hye Yoo, Dong-Yeop Shin
Patients with hematologic malignancies (HMs) often face challenges in accessing palliative care (PC) and receiving quality end-of-life (EOL) care. We examined factors associated with referrals to tertiary PC and the effects of tertiary PC on EOL care in patients with HMs.
-
Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-02 Vanja Zeremski, Louisa Adolph, Sina Beer, Mirjeta Berisha, Benedikt Jacobs, Christoph Kahl, Christian Koenecke, Siegfried Kropf, Jens Panse, Judith Petersen, Martin Schmidt-Hieber, Jessica Schneider, Vladan Vucinic, Jeanette Walter, Oliver Weigert, Hanno M. Witte, Dimitrios Mougiakakos
Treatment intensification (including consolidative high-dose chemotherapy with autologous stem cell transplantation [HDT-ASCT]) significantly improved outcome in primary central nervous system lymphoma (PCNSL) patients.
-
Delayed diagnostic interval and survival outcomes in pediatric leukemia: A single-center, retrospective study Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-28 Kosuke Tamefusa, Motoharu Ochi, Hisashi Ishida, Takahiro Shiwaku, Kiichiro Kanamitsu, Kaori Fujiwara, Yasuhisa Tatebe, Naomi Matsumoto, Kana Washio, Hirokazu Tsukahara
This study primarily focused on the diagnostic interval (DI), defined as the duration from the onset of leukemic symptoms to diagnosis. We investigated whether a prolonged DI is associated with the outcomes of pediatric leukemia.
-
Outcomes in Kaposi's sarcoma-associated herpesvirus -associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (HIV) in a safety-net hospital system Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-28 Melanie Lopez, Radhika Kainthla, Susana Lazarte, Weina Chen, Ank E. Nijhawan, Sheena Knights
To describe cases of Kaposi's sarcoma-associated herpesvirus (KSHV)-associated multicentric Castleman's disease (MCD) and primary effusion lymphoma (PEL) in patients with HIV from a large, safety-net hospital system in Dallas, Texas, USA.
-
Enhancing thalassemia gene carrier identification in non-anemic populations using artificial intelligence erythrocyte morphology analysis and machine learning Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-28 Fan Zhang, Jieyu Zhan, Yang Wang, Jing Cheng, Meinan Wang, Peisong Chen, Juan Ouyang, Junxun Li
Non-anemic thalassemia trait (TT) accounted for a high proportion of TT cases in South China.
-
Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-25 Moritz Lehne, K. Martin Kortüm, Karthik Ramasamy, Elena Zamagni, Tim d'Estrubé, Evi Zhuleku, Maya Hanna, Soham Shukla, Marco Ghiani, Ulf Maywald, Thomas Wilke, Lenka Kellermann, Sue Perera
To retrospectively analyze real-world treatment patterns in patients with relapsed/refractory multiple myeloma (RRMM) who initiated third-line treatment in Europe.
-
Use of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: A clinical practice survey Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-20 Allison Mo, Robert Weinkove, Erica M. Wood, Jake Shortt, Anna Johnston, Zoe K. McQuilten
Thrombocytopenia and bleeding are common in myelodysplastic syndromes (MDS), but optimal management is unknown. We conducted a survey to identify current clinical practice regarding platelet transfusion (PLT-T) and tranexamic acid (TXA) to inform future trial design.
-
Screening for multidrug-resistant organisms in high-risk hospitalized patients with hematologic diseases Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-20 Valentine Delanote, Rutger Callens, Dirk Vogelaers, Dries Deeren
Patients treated for hematologic malignancies are at higher risk for blood stream infections (BSI) and multidrug-resistant organisms (MDRO) are increasingly involved. Studies showed a significant association between rectal colonization status and a higher risk of subsequent MDRO BSI. The objective of our study was to probe the practice of surveillance cultures in Belgian hematology centers.
-
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-20 Clement Twumasi, Sally Moore, Ross Sadler, Sally Jeans, Sherin Varghese, Alison Turner, Gaurav Agarwal, Jemma Larham, Nathanael Gray, Oluremi Carty, Joe Barrett, Stella Bowcock, Udo Oppermann, Vicky Gamble, Gordon Cook, Chara Kyriakou, Mark Drayson, Supratik Basu, Sarah McDonald, Shelagh McKinley, Sarah Gooding, Muhammad K. Javaid, Karthik Ramasamy
To describe determinants of persisting humoral and cellular immune response to the second COVID-19 vaccination among patients with myeloma.
-
Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-17 Supriya Gupta, Mira Kohorst, Hassan B. Alkhateeb
Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive B-cell neoplasm associated with poor outcomes. Conventional multiagent chemotherapy and bispecific antibody therapy may induce remission; however, relapse rates remain high and overall survival is poor. Chimeric antigen receptor T-cell (CAR-T) therapy provides durable, deep complete remission, and long-term cures in
-
Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-19 Tetsuya Mori, Tomoo Osumi, Akiko Kada, Kentaro Ohki, Yuhki Koga, Reiji Fukano, Naoto Fujita, Tetsuo Mitsui, Takeshi Mori, Akiko M. Saito, Atsuko Nakazawa, Ryoji Kobayashi, Masahiro Sekimizu
The benefit of adding rituximab to standard lymphomes malins B (LMB) chemotherapy for children with high-risk mature B-cell non-Hodgkin lymphoma (B-NHL) has previously been demonstrated in an international randomized phase III trial, to which the Japanese Pediatric Leukemia/Lymphoma Study Group could not participate.
-
The Haemato-Oncology Frailty (HOF) score to assess frailty in lymphoma Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-19 Hena Ramdany, Thomas Lofaro, Simona Deplano
Morbidity and mortality during chemotherapy in older adults with haematological malignancy can be unpredictable. The Haemato-Oncology Frailty (HOF) score was previously found to predict outcomes in a cohort of patients with plasma cell myeloma. In this study, we assess its utility in assessing frailty in patients with lymphoma, and compare its performance to that of two other frailty scores. The HOF
-
A diagnostic challenge—First case of chronic lymphatic leukemia-associated necrotizing sweet syndrome Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-17 Marie Anne-Catherine Neumann, Pascal Nieper, Florian Simon, Alexander Shimabukuro-Vornhagen, Michael Hallek, Jorge Garcia Borrega
Sweet syndrome, also known as acute febrile neutrophilic dermatosis, is a rare disorder typically characterized by the clinical triad including a sudden onset of fever, painful skin lesions, and neutrophilia. The histopathological findings are a dense neutrophilic infiltrate and oedema of the dermis and epidermis without evidence of a vasculitis. Besides treatment of the underlying cause, sweet syndrome
-
Update on the current and future use of CAR-T to treat multiple myeloma Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-15 Zhubin Gahvari, Matthew Brunner, Timothy Schmidt, Natalie S. Callander
Chimeric antigen receptor T-cell (CAR-T) therapy has become an important intervention in the management of relapsed and relapsed/refractory multiple myeloma (MM). Currently, B-cell maturation antigen (BCMA) is the most targeted surface protein due to its ubiquitous expression on plasma cells, with increasing expression of this essential transmembrane protein on malignant plasma cells as patients develop
-
Clinical and pathological features of clonal cytopenia of undetermined significance presenting with isolated thrombocytopenia (CCUS-IT) Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-13 Caitlin O'Neill, Nneka Nwachukwu, Maria Vergara-Lluri, Ashley Hagiya, Casey L. O'Connell
Clonal cytopenia of undetermined significance (CCUS) is defined as somatic mutations of myeloid malignancy-associated genes in the blood or bone marrow with one or more persistent unexplained cytopenias that do not meet diagnostic criteria for a defined myeloid neoplasm. CCUS with isolated thrombocytopenia (CCUS-IT) is rare.
-
Comparison of bleeding and thrombotic outcomes in veno-venous extracorporeal membrane oxygenation: Heparin versus bivalirudin Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-13 Thomas Kartika, Rick Mathews, Gina Migneco, Taylor Bundy, Andy J. Kaempf, Michael Pfeffer, Thomas G. DeLoughery, Kerry Moore, Rachel Beardshear, Heath J. Oetken, Jonathan Case, Monica T. Hinds, Owen J. T. McCarty, Joseph J. Shatzel, David Zonies, Bishoy Zakhary
We aimed to evaluate thrombotic and hemorrhagic complications with heparin versus bivalirudin use in veno-venous extracorporeal membrane oxygenation (V-V ECMO).
-
Risk-based and individualised management of bleeding and thrombotic events in adults with primary immune thrombocytopenia (ITP) Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-13 Catherine Lambert, Hillary Maitland, Waleed Ghanima
Although bleeding is one of the main symptoms of primary immune thrombocytopenia (ITP), risk factors for bleeding have yet to be fully established. Low platelet count (PC; <20–30 × 109/L) is generally indicative of increased risk of bleeding. However, PC and bleeding events cannot be fully correlated; many other patient- and disease-related factors are thought to contribute to increased bleeding risk
-
The current challenges faced by people with hemophilia B Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-11 Wolfgang Miesbach, Annette von Drygalski, Clive Smith, Krupa Sivamurthy, Karen Pinachyan, Debbie Bensen-Kennedy, Douglass Drelich, Roshni Kulkarni
Hemophilia B (HB) is a rare, hereditary disease caused by a defect in the gene encoding factor IX (FIX) and leads to varying degrees of coagulation deficiency. The prevailing treatment for people with HB (PWHB) is FIX replacement product. The advent of recombinant coagulation products ushered in a new era of safety, efficacy, and improved availability compared with plasma-derived products. For people
-
Flow cytometry for comprehensive assessment of platelet functional activity in response to ADP stimulation Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-11 Evgeniya A. Ponomarenko, Anastasia A. Ignatova, Dmitrii M. Polokhov, Aleksandra A. Filkova, Elena V. Suntsova, Pavel A. Zharkov, Daria V. Fedorova, Alexandra S. Pisaryuk, Imad Meray, Zhanna D. Kobalava, Yokubjon S. Tukhsanboev, Alexey A. Maschan, Galina A. Novichkova, Anastasia N. Sveshnikova, Mikhail A. Panteleev
Flow cytometry with adenosine diphosphate (ADP) allows to characterize molecular changes of platelet function caused by this physiologically important activation, but the methodology has not been thoroughly investigated, standardized and characterized yet. We analyzed the influence of several major variables and chose optimal conditions for platelet function assessment.
-
Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-03 William Wesson, Nausheen Ahmed, Aliya Rashid, Carine Tabak, Emerson Logan, Jose Marchena-Burgos, Maggie Nelson, James A. Davis, Mary McGann, Leyla Shune, Marc Hoffmann, Al-Ola Abdallah, Hamza Hashmi
While chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment outcomes of relapsed/refractory hematological malignancies, this therapy is associated with post-treatment cytopenias, which can pose a challenge to its safe administration. This study describes the management of post-CAR T cytopenias using the thrombopoietin mimetic eltrombopag.
-
Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients Eur. J. Haematol. (IF 3.1) Pub Date : 2023-11-29 C. Petit, C. Saillard, B. Mohty, Y. Hicheri, F. Villetard, V. Maisano, A. Charbonnier, J. Rey, E. D‘Incan, C. Rouzaud, V. Gelsi-Boyer, A. Murati, A. C. Lhoumeau, A. Ittel, M. J. Mozziconacci, A. S. Alary, M.-A. Hospital, N. Vey, S. Garciaz
To compare the efficacy of venetoclax-azacitidine (VEN–AZA) with AZA in the real-life for patients with first relapsed or refractory acute myeloid leukaemia (R/R AML).
-
Hydroxyurea at escalated dose versus fixed low-dose hydroxyurea in adults with sickle cell disease Eur. J. Haematol. (IF 3.1) Pub Date : 2023-11-29 Ugochi O. Ogu, Ayesha Mukhopadhyay, Kruti Patel, Marquita N. Nelson, KayLee S. Strahan, Lin Wu, Matthew P. Smeltzer, Kenneth I. Ataga
Hydroxyurea reduces the frequency of vaso-occlusive complications, increases hemoglobin, and decreases mortality in sickle cell disease (SCD). Although current guidelines recommend escalation to maximum tolerated dose (MTD), the use of fixed low-dose hydroxyurea is common in low-resource countries. We conducted a systematic review and meta-analysis to evaluate the efficacy of escalated doses versus
-
The disease burden of paroxysmal nocturnal hemoglobinuria in Denmark: Epidemiology, survival, healthcare resource utilization, costs, treatment gaps, and labor market attachment Eur. J. Haematol. (IF 3.1) Pub Date : 2023-11-27 Carly Rich, Koo Wilson, Jens Olsen, Mikkel Pedersen, Henrik Frederiksen
To establish epidemiology, healthcare costs, and labor market attachment in patients with paroxysmal nocturnal hemoglobinuria (Pt-PNH) in Denmark.
-
Adult-onset Still's disease with concurrent thrombotic microangiopathy: Observations from pooled analysis for an uncommon finding Eur. J. Haematol. (IF 3.1) Pub Date : 2023-11-23 Anil Ananthaneni, Gaelen Shimkus, Francesca Weis, Eunice Adu-Dapaah, Rachaita Lakra, Poornima Ramadas, Samina Hayat
Adult-onset Still's disease (AOSD) is a rare systemic inflammatory disorder that is characterized by quotidian fevers, arthritis, and an evanescent rash. Occurrence of concurrent thrombotic microangiopathy (TMA) in AOSD is rare. The treatment aspects of TMA in AOSD are actively being debated.
-
Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health-related quality of life and productivity Eur. J. Haematol. (IF 3.1) Pub Date : 2023-11-23 Koo Wilson, Carly Rich, Zalmai Hakimi, Regina Horneff, Jesse Fishman, Jennifer Mellor, Lucy Earl, Yasmin Taylor, Alice Simons, Joe Conyers, Brian Mulherin, Elaine Majerus, Alexander Röth
To describe real-world use/effectiveness of pegcetacoplan (PEG) in paroxysmal nocturnal haemoglobinuria (PNH).
-
Chronic myeloid leukemia (CML) in children and adolescents—Clinicopathological findings Eur. J. Haematol. (IF 3.1) Pub Date : 2023-11-20 Louis Nevejan, Veerle Labarque, Nancy Boeckx
Barely two per million Belgian children/adolescents are diagnosed with chronic myeloid leukemia (CML) annually. In this retrospective study, we aimed to investigate the diagnostic features, clinical and laboratory characteristics, and treatment outcome of this rare entity.
-
Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method Eur. J. Haematol. (IF 3.1) Pub Date : 2023-11-20
CONFLICT OF INTEREST STATEMENT Craig M. Kessler: Research support from Bayer, Octapharma; Consultancy for Bayer; Scientific Advisory Board for Bayer, CSL Behring, Genentech, Novo Nordisk, Octapharma; Other: Bayer (Chair, DSMB). Fernando F. Corrales-Medina: Research grant from Bayer; Advisory Board Member for Bayer, CSL Behring, Genentech, Octapharma, Takeda; Educational grant from Octapharma. Pier
-
Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study Eur. J. Haematol. (IF 3.1) Pub Date : 2023-11-20 Damian A. Laber, Parth C. Patel, Constantine N. Logothetis, Ankita K. Patel, Michael Jaglal, Mintallah Haider, Nathan Visweshwar, Geetha Rajasekaran-Rathnakumar, Jennifer Eatrides
Complement-mediated thrombotic microangiopathy (CM-TMA), also called atypical hemolytic uremic syndrome (aHUS), is a difficult-to-diagnose rare disease that carries severe morbidity and mortality. Anti-C5 monoclonal antibodies (aC5-mab) are standard treatments, but large studies and long-term data are scarce. Here, we report our single institution experience to augment the knowledge of CM-TMA treated
-
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study Eur. J. Haematol. (IF 3.1) Pub Date : 2023-11-15 Fredrik H. Schjesvold, Heinz Ludwig, Maria-Victoria Mateos, Alessandra Larocca, Haifaa Abdulhaq, Stefan Norin, Marcus Thuresson, Nicolaas A. Bakker, Paul G. Richardson, Pieter Sonneveld
Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone demonstrated superior progression-free survival (PFS), but not overall survival (OS), versus pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma in the OCEAN study. Time to progression (TTP) <36 months after a prior autologous stem cell transplantation (ASCT) was a negative
-
DNMTs-mediated SOCS3 methylation promotes the occurrence and development of AML Eur. J. Haematol. (IF 3.1) Pub Date : 2023-11-11 Xiaohui Zhang, Kai Zhang, Jing Zhang, Wei Chang, Yunguo Zhao, Xiaohui Suo
As a tumor suppressor gene, SOCS3 inhibits the growth of tumor cells by regulating JAK/STAT signaling pathway through negative feedback. This study aimed to investigate the biological function and mechanism of SOCS3 methylation mediated by DNMTs in the development of AML.